Answers are grounded in this paper and cite their sources.
Treatment opportunities using the enfortumab vedotin plus pembrolizumab (EV+P) combination are expanding for patients with unresectable or metastatic urothelial carcinoma. We report the case of a 93-year-old man with bladder cancer and lung metastases who received EV+P therapy and achieved a complete response. By omitting the dose on EV Day 8 and then extending the dosing interval based on adverse events and patient-reported outcomes, it was possible to continue treatment while maintaining complete response.
No takes yet. Share an insight, caveat, or question.
Jojima et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: